More than 3,000 drugs have already either been developed or repurposed with the assistance of AI. Credit: ART STOCK CREATIVE / Shutterstock. A recent survey found that 82% of pharmaceutical industry professionals believe that digital transformation will either significantly or moderately shorten the drug development timeline. The survey was conducted by analytics company GlobalData, which is the parent company of Pharmaceutical Technology. It found that, of 107 responses, only 3% deemed that digital transformation would have no impact on the drug development timeline while almost half (47%) expected the timeline to be moderately shortened. Commenting on the results Urte Jakimaviciute, senior director of market research and strategic intelligence at GlobalData, said: “Survey findings highlight that the growing recognition within the pharmaceutical industry that technology, particularly AI, is accelerating innovation and efficiency in the drug discovery and development process, enabling processes such as faster identification of potential drug candidates and optimisation clinical trials processes.” In a separate survey published in September, respondents were asked how disruptive they anticipated a variety of technologies to be within pharmaceuticals. AI emerged as the most disruptive, with 53.2% considering the disruption to be significant and 21% quantifying it as slight. Respondents also considered target […]
Click here to view original web page at www.pharmaceutical-technology.com
